What Is the Cure Rate of Heavy Ion Therapy? (As of 2026)

There is no separate figure for the cure rate or survival rate of heavy ion therapy itself in National Cancer Information Center or NCCN materials, and because cure rates vary by cancer type, stage, and patient condition, it is difficult to state a single unified number for heavy ion therapy as a standalone treatment method. That said, for prostate cancer—the representative cancer type for which heavy ion therapy is actually applied—Korea's overall 5-year relative survival rate is reported at 96.9%.

Key Takeaways

• There is no officially compiled cure rate or survival rate statistic for heavy ion therapy alone; survival rates are published by cancer type and stage.
• For prostate cancer, the representative cancer type for which heavy ion therapy is used, Korea's 5-year relative survival rate is 96.9% (National Cancer Registration Statistics 2019–2023, National Cancer Center Korea Central Cancer Registry).
• This figure is a nationwide statistic for prostate cancer overall across all treatment methods—including surgery and radiation therapy—and is not a result specific to heavy ion therapy alone.
• Korea began its first domestic heavy ion therapy in 2023, with the main targets being localized stage 1–3 solid tumors.
• Heavy ion therapy is a treatment with defined indications, and it is not the standard treatment for cancers that have spread to multiple organs or for blood cancers.

Why Isn't There a Separate Cure Rate for Heavy Ion Therapy Alone?

• This is because cure rates and survival rates are compiled as national statistics by cancer type and stage, not by treatment method. The 5-year relative survival rates published by the National Cancer Information Center and the National Cancer Center Korea Central Cancer Registry are calculated for entire cancer types such as prostate cancer or liver cancer, not broken down by specific equipment or treatment technique.
• Heavy ion therapy is a type of radiation therapy, classified specifically as particle therapy. Thanks to the Bragg peak property—where carbon ions stop at the depth of the tumor and release energy intensively at that point—normal tissue in front of and behind the tumor sustains less damage, and it can also be attempted on tumors that responded poorly to conventional X-ray radiation.
• Therefore, to answer the question 'what is the cure rate of heavy ion therapy,' one must first specify which cancer and which stage the heavy ion therapy was given for. Even for the same cancer, outcomes can vary depending on the tumor's location, size, and prior treatment history.

How Should the Prostate Cancer Numbers Be Interpreted?

• Prostate cancer is the representative cancer type for which heavy ion therapy began to be applied in Korea starting in 2023. It is used in a format completing around 12 sessions for localized prostate cancer, and whether it can be applied depends on prior radiation history, presence of an artificial hip joint, and the condition of the bowel and bladder.
• Korea's 5-year relative survival rate for prostate cancer of 96.9% (National Cancer Registration Statistics 2019–2023) is an average figure for the entire group of prostate cancer patients across all treatment methods—including surgery, radiation therapy, heavy ion therapy, and hormone therapy—and represents a 37.7 percentage point increase compared to patients diagnosed in 1993–1995. It is important to note that this is not the survival rate of a patient group that received heavy ion therapy alone.
• For reference, the U.S. SEER statistics (2016–2022) report a 5-year relative survival rate of 98.2% for prostate cancer, and both figures are nationwide statistics rather than the results of any specific hospital. Survival rates are group averages and are not numbers that predict an individual's outcome.

How Is Cure Confirmed?

• Step 1 — Changes in the tumor do not appear immediately on imaging right after treatment; it is common for the tumor to still appear on imaging taken immediately after treatment, and this does not mean the treatment failed.
• Step 2 — Over the course of several months, CT and MRI imaging is used to confirm whether the tumor has actually shrunk.
• Step 3 — Recurrence is monitored by following a follow-up schedule tailored to the cancer type (for example, prostate cancer follow-up centers on PSA levels).
• Step 4 — Because some side effects appear late at the treatment site, long-term follow-up tailored to the treated area continues.

FAQ — Is It True That Heavy Ion Therapy Gives a Better Cure Rate for All Cancers?

No. Heavy ion therapy is a treatment with defined indications, and this does not mean it is a better treatment for all cancers. Its main targets are localized solid tumors (prostate cancer, hepatocellular carcinoma, some lung cancers, pancreatic cancer, bone and soft tissue sarcomas, etc.). Cancers that have spread to multiple organs, cancers that grow broadly along organ walls such as stomach cancer and colorectal cancer, and blood cancers such as leukemia and lymphoma are not standard indications—in these cases, surgery, standard radiation therapy, or drug therapy are better choices.

FAQ — Does the Cure Rate Differ From Proton Therapy?

There is no national statistic directly comparing cure rates between the two, and the choice between the two treatments is not about which is 'better' but which is 'more suitable.' Proton therapy is considered in situations where protecting normal tissue is especially critical (pediatric cancers, tumors near the eyes, brain, or spinal cord), while heavy ion therapy is considered for tumors that respond poorly to conventional radiation, since carbon ions are heavier than protons and break DNA more strongly. Which option is appropriate is determined based on stage and location and laid out in a written opinion.

Sources and Notes

• This article was written based on notes on heavy ion therapy, proton therapy, radiation therapy, and prostate cancer (National Cancer Information Center, National Cancer Center Korea, NCCN patient guidelines, National Cancer Registration Statistics 2019–2023, SEER 2016–2022).
• This content is intended for general medical information purposes, and diagnosis, treatment methods, and outcomes may vary depending on an individual's condition. Accurate diagnosis and treatment should always be determined through consultation with medical staff.